Clinical Trials Logo

Neurodermatitis clinical trials

View clinical trials related to Neurodermatitis.

Filter by:

NCT ID: NCT03858634 Completed - Plaque Psoriasis Clinical Trials

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Start date: May 29, 2019
Phase: Phase 2
Study type: Interventional

Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study. The diseases characterized by chronic pruritus investigated in this pilot study currently include chronic idiopathic urticaria (CIU), chronic idiopathic pruritus (CIP), lichen planus (LP), lichen simplex chronicus (LSC) and plaque psoriasis (PPs).

NCT ID: NCT03816891 Completed - Prurigo Nodularis Clinical Trials

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Start date: March 11, 2019
Phase: Phase 2
Study type: Interventional

Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.

NCT ID: NCT03677401 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT03630198 Completed - Plaque Psoriasis Clinical Trials

Pain Outcomes Following Intralesional Corticosteroid Injections

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment. Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure. The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.

NCT ID: NCT03568136 Completed - Dermatitis, Atopic Clinical Trials

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

Secu_in_AD
Start date: September 18, 2018
Phase: Phase 2
Study type: Interventional

The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

NCT ID: NCT03546816 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: May 2, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT02732145 Completed - Vulvodynia Clinical Trials

Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis

DATRIV
Start date: December 2011
Phase: N/A
Study type: Interventional

The objective of the study was to determine sensitivity, specificity and diagnostic accuracy of "Three Rings Vulvoscopy" for detection of vulvar dermatosis using histopathology as the reference standard.

NCT ID: NCT02196324 Completed - Prurigo Nodularis Clinical Trials

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Start date: July 9, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.

NCT ID: NCT02174432 Completed - Prurigo Nodularis Clinical Trials

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Start date: August 15, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

NCT ID: NCT02174419 Completed - Pruritus Clinical Trials

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Start date: March 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to evaluate the safety and tolerability in the study population.